 for saphenous incompetence, with or without
concomitant phlebectomy, we suggest postprocedure compression therapy for a
minimum of 1 week for pain reduction.
3. Pharmacological treatment

a

C (low to
very low)

These products are not approved drugs by the U.S. Food and Drug Administration (FDA). The FDA does not approve medical food
or nutritional supplements (https://www.fda.gov/).
4.1. Endovenous ablation vs high ligation and stripping (HL&S)

Guidelines

Grade of
recommendation

Quality of
Evidence

4.1.1.

1 (strong)

B
(moderate)

For patients with symptomatic varicose veins and axial reﬂux in the GSV, who are
candidates for intervention, we recommend treatment with endovenous ablation over
HL&S of the GSV.

(Continued on next page)

4

Gloviczki et al

Journal of Vascular Surgery: Venous and Lymphatic Disorders
January 2024

Continued.
4.1. Endovenous ablation vs high ligation and stripping (HL&S)
4.1.2.

For patients with symptomatic varicose veins and axial reﬂux in the SSV, who are
candidates for intervention, we recommend treatment with endovenous ablation over
ligation and stripping of the SSV.

1 (strong)

C (low to
very low)

4.1.3.

For patients with symptomatic varicose veins and axial reﬂux in the AAGSV or PAGSV, who 2 (weak)
are candidates for intervention, we suggest treatment with endovenous ablation, with
additional phlebectomy, if needed, over ligation and stripping of the accessory vein.

C (low to
very low)

4.1.4.

For patients with symptomatic varicose veins and axial reﬂux in the GSV or SSV, we
recommend treatment with HL&S of the saphenous vein if technology or expertise in
endovenous ablation is not available or if the venous anatomy precludes endovenous
treatment.

B
(moderate)

4.1.5.

For patients with symptomatic varicose veins and axial reﬂux in the AAGSV or PAGSV, we 2 (weak